What the anaesthetists said, and then said again
What endoscopic and ultrasound studies found about residual gastric content, and what the aspiration data does and does not support.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Page 11 of 11 of this archive, newest first.
What endoscopic and ultrasound studies found about residual gastric content, and what the aspiration data does and does not support.
What the pivotal programmes measured and how often, which is a more defensible template than most published monitoring schedules.
What the Journal would want measured before treating this as settled in either direction.
Trial adverse-event tables count episodes reported to a study nurse. They are the best data we have and they systematically under-record the mundane.
We set out the questions that distinguish a symptom to manage from a dose to change.
The gap between a defensible recommendation and a confident one is where most of the harm in this subject lives.
Three different explanations for the same abnormal number, and how to tell them apart.
Rapid weight loss by any means raises gallstone risk. Separating that from a direct drug effect requires a comparator, and the trials have one.
Three different explanations for the same abnormal number, and how to tell them apart.
The panel drawn during a week of vomiting is measuring the vomiting.
Weight loss reduces bone mineral density at load-bearing sites. Whether that translates into fractures in this population is unmeasured.
Pancreatitis is rare, was adjudicated in the outcome programmes, and did not show the imbalance early case reports suggested.
The features that should prompt urgent assessment, stated once and plainly.
Almost every figure in circulation about tolerability comes from six publications. This is what they say.